.: www.youthXchange.net - BRAND-NAME VS. GENERIC DRUGS :.

GENERAL DATA
ENVIRONMENT
BASIC NEEDS
nutrition
> food demand/supply
> food safety
> consumers information

health
> health system
> health/lifestyles
> health/environment
> HIV/AIDS

housing
> demand/supply
> home quality
> urban overview

education
> access & participation
> resources

labour
> people rights
> behind products

OTHER NEEDS

facts & figures

HEALTH

BRAND-NAME VS. GENERIC DRUGS

source: www.accessmed-msf.org
/prod/publications.asp?scntid=
2620031731143&contenttype=PARA&

www.who.int/medicines/
strategy/access/stacstrat.
shtml

Patents drive drug prices up…

for example, a country that is required to purchase brand name drugs from Western industry will spend more than US$ 1,500 a year per patient for standard AIDS therapy.

Equivalent generic drugs are available for US$ 350 per patient per year. In other words, 5 times more people could be treated on the same budget.

Although Anti-Retroviral therapy (ARV) for AIDS is more affordable and has been proven to be efficient even in poor settings, only 400,000 out of 6 million people in need have access to this life-prolonging treatment.

The 3-by-5 Initiative* was created to help 3 million AIDS patients in the developing world to get ARV therapy by the year 2005. It will buy massive quantities of fixed-dose generics for as low as US$140 per person/per year.

* Launched by the Global Fund, the Clinton Foundation, UNICEF, and the World Bank.

[ home | UNEP/UNESCO contact | partners | YXC Team ]